HCA Healthcare (HCA) Reports Promising Gene-Editing Therapy Study Results

HCA Healthcare, Inc. (NYSE:HCA) is one of the 10 Most Undervalued American Stocks to Invest In.

On June 29, 2026, HCA Healthcare, Inc. (NYSE:HCA) announced new research published in The New England Journal of Medicine showing promising results from a gene-editing therapy being investigated in children ages 5-11 with severe sickle cell disease and transfusion-dependent beta thalassemia. The study evaluated exa-cel, a CRISPR-based cell therapy currently approved by the U.S. Food and Drug Administration for eligible patients ages 12 and older with sickle cell disease and transfusion-dependent beta thalassemia. Among participants followed long enough to evaluate the primary endpoints, all eight children with beta thalassemia achieved transfusion independence for at least 12 months, while all eight children with sickle cell disease remained free from severe vaso-occlusive crises for at least 12 months.

On June 22, TD Cowen analyst Ryan Langston lowered the firm’s price target on HCA Healthcare to $431 from $500 and kept a Buy rating. Langston reduced TD Cowen’s 2026 and 2027 growth assumptions after its May hospital survey showed flat year-over-year revenue. Survey commentary pointed to weaker surgical volumes that were partially offset by growth in medical volumes.

HCA Healthcare (HCA) Reports Promising Gene-Editing Therapy Study Results

In an 8-K filing, HCA Healthcare said Dr. Michael Cuffe and the company agreed on June 15 that Dr. Cuffe will step down as Executive Vice President and Chief Clinical Officer effective August 31, 2026. Dr. Cuffe will then continue in a transitional role with the company until February 2027 and will be eligible to receive benefits under HCA Healthcare’s executive severance policy and applicable incentive plans.

HCA Healthcare, Inc. (NYSE:HCA) provides health care services in the United States.

While we acknowledge the risk and potential of HCA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than HCA and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1